Correlation of Serum Levels of Interleukine-16, CCL27, Tumor Necrosis Factor-related Apoptosis-inducing Ligand, and B-cell Activating Factor  with Multiple Sclerosis Severity

Ebrahim Kouchaki; Hossein Akbari; Fatemeh Mahmoudi; Mahdi Salehi; Effat  Naim; Hassan Nikoueinejad

doi:10.18502/ijaai.v21i1.8610

Ebrahim Kouchaki Department of Neurology, Kashan University of Medical Sciences, Kashan, Iran
Hossein Akbari Department of Biostatistics and Public Health, Kashan University of Medical Sciences, Kashan, Iran
Fatemeh Mahmoudi Department of Neurology, Kashan University of Medical Sciences, Kashan, Iran
Mahdi Salehi Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran
Effat Naim Chemical Injuries Research Center, System Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
Hassan Nikoueinejad Nephrology and Urology Research Centre, Baqiyatallah University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/ijaai.v21i1.8610

Keywords: B cell-activating factor; Chemokine CCL27; Multiple sclerosis; TNF-related apoptosis-inducing ligand

Abstract

The pathogenic roles of Interleukine-16 (IL-16), CCL27, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and B-cell activating factor (BAFF) has been shown in some autoimmune and inflammatory diseases. We aimed to correlate the circulatory changes of such factors with the severity of disease in patients with multiple sclerosis (MS).

This case-control study was conducted on 84 MS patients and 83 healthy controls. We measured the serum levels of IL-16, CCL27, TRAIL, and BAFF in all participants by enzyme-linked immune sorbent assay. Using the expanded disability status scale (EDSS), we evaluated the severity of MS. Finally, we assessed the correlation between serum levels of such factors with the severity of MS.

We found increased serum levels of CCL27, IL-16, and BAFF in patients with MS compared to those in healthy subjects. However, no difference was found in serum levels of TRAIL between the patients and controls. In addition, a significant positive correlation between serum levels of CCL27, IL-16, TRAIL, and BAFF with disease severity according to EDSS score was determined.

We showed higher serum levels of CCL27, BAFF, TRAIL, and IL-16 in MS patients with more severe disabilities than mild forms. Such finding may represent their contribution to the pathogenesis of MS. Blocking such molecules may yield new treatments for MS.